Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x100px

Document › Details

Immatics N.V.. (8/9/22). "Press Release: Immatics Announces Second Quarter 2022 Financial Results and Business Update". Tübingen & Houston, TX.

	Organisation	Immatics N.V. (Nasdaq: IMTX)
	Group	Immatics (Group)
	Organisation 2	Editas Medicine Inc. (Nasdaq: EDIT)
	Product	IMA203 TCR-T candidate targeting PRAME (ACTengine)
	Product 2	ACTallo® platform (allogeneic gamma delta T cell therapy platform)
	Person	Singh, Harpreet (Immatics 201907– CEO before CSO + CEO of Immatics US + Co-Founder)
	Person 2	Valente, Nancy (Immatics 202203– Non-executive Board Director formerly at Genentech/Roche)

Original document
accessed by [iito] on 2022-09-05

Record changed: 2023-06-05

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for Immatics (Group)

[1] Immatics N.V.. (10/24/23). "Press Release: Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy". Houston, TX & Tübingen....
[2] Immatics N.V.. (9/11/23). "Press Release: Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics". Cambridge, MA & Tübingen....
[3] Immatics N.V.. (7/24/23). "Press Release: Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb". Tübingen & Houston, TX....
[4] Immatics N.V.. (5/2/23). "Press Release: Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine IMA203 TCR-T Targeting PRAME". Houston, TX & Tübingen....
[5] MicrofluidX Ltd.. (5/2/23). "Press Release: MicrofluidX and Immatics Working Together on Automated End-to-End Bioprocessing for TCR-T Therapies". Stevenage & Houston, TX....
[6] Immatics N.V.. (5/1/23). "Press Release: Immatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic Collaboration". Tübingen & Houston, TX....
[7] Immatics N.V.. (10/10/22). "Press Release: Immatics Announces $110 Million Underwritten Offering of Ordinary Shares". Houston, TX & Tübingen....
[8] Immatics N.V.. (10/10/22). "Press Release: Immatics Reports Interim Clinical Data Update on ACTengine IMA203 TCR-T Monotherapy Targeting PRAME". Houston, TX & Tübingen....
[9] Immatics N.V.. (9/10/22). "Press Release: Immatics Presents Comprehensive Preclinical Data Set for TCR Bispecific Candidate IMA402 Targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022". Houston, TX & Tübingen....
[10] AiCuris Anti-infective Cures AG. (9/1/22). "Press Release: AiCuris Appoints Experienced Business Leader Dr. Sabrina Kuttruff-Coqui as Chief Financial Officer". Wuppertal....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]